Cargando…

INHIBITION OF PACLITAXEL AGAINST NEUROGLIOMA CELLS U251 GROWTH AND ITS MECHANISM

BACKGROUND: Glioma is the most common primary tumor of the central nervous system, and accounted for about 70% of primary tumors. MATERIALS AND METHODS: In the study, antitumour activity and mechanism of paclitaxel was investigated. Different concentrations of paclitaxel (200, 300, 400 μmol/L) was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, ShiMeng, Yu, Fang, Yang, ChunYan, Hao, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: African Traditional Herbal Medicine Supporters Initiative (ATHMSI) 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411869/
https://www.ncbi.nlm.nih.gov/pubmed/28480395
http://dx.doi.org/10.21010/ajtcam.v14i1.19
Descripción
Sumario:BACKGROUND: Glioma is the most common primary tumor of the central nervous system, and accounted for about 70% of primary tumors. MATERIALS AND METHODS: In the study, antitumour activity and mechanism of paclitaxel was investigated. Different concentrations of paclitaxel (200, 300, 400 μmol/L) was treated in neuroglioma cellsU251. RESULTS: Paclitaxel significantly inhibited neuroglioma cells growth, and promoted its apoptosis. Paclitaxel can block tumour cells in the G2/M phase. In addition, apoptosis-related genes caspase-3 and bax expressions were increased after paclitaxel treatment. CONCLUSION: Our work indicated that paclitaxel displayed strong anti-tumour activity.